brilanestrant

Drug Overview

Brilanestrant is an experimental cancer medicine that belongs to a modern group of Targeted Therapies. It was designed specifically to treat advanced breast cancer that depends on hormones to grow. While many older hormone therapies require painful monthly injections, brilanestrant was developed as a convenient pill that patients could take at home.

Although it showed early promise as a “Smart Drug” in the fight against breast cancer, it is important to note that its clinical development was ultimately stopped. Researchers use the data from brilanestrant trials to help build even better, newer versions of this type of medication today.

• Generic Name: Brilanestrant (also known in research as ARN-810 or GDC-0810)
• US Brand Names: None (Investigational Agent)
• Drug Class: Oral Selective Estrogen Receptor Degrader (SERD) / Anti-estrogen
• Route of Administration: Oral (taken by mouth as a tablet or capsule)
• FDA Approval Status: Not FDA Approved. It is an investigational drug whose clinical development was discontinued.

What Is It and How Does It Work? (Mechanism of Action)

Brilanestrant is a Targeted Therapy designed to shut down the cellular machinery that feeds certain breast cancers. To understand how it works, we must look at how hormone-receptor-positive (ER+) breast cancer grows.

In normal breast tissue, the hormone estrogen binds to “estrogen receptors” (ER) inside the cell. Think of estrogen as a key and the receptor as the ignition switch. When the key turns, the cell gets the signal to grow and divide. In ER+ breast cancer, the cancer cells have too many of these ignition switches, causing them to multiply out of control.

At the molecular level, brilanestrant works in a unique, two-step process to stop this:

1. Blocking the Switch (Antagonism): First, the drug acts as a fake key. It binds tightly to the estrogen receptor so that real estrogen cannot attach to it.
2. Destroying the Switch (Degradation): Once brilanestrant binds to the receptor, it changes the receptor’s physical shape. The cell’s internal trash-disposal system (called the proteasome) recognizes this bent shape as “damaged” and destroys the estrogen receptor completely.

Because the receptor is permanently destroyed, the cancer cell can no longer receive the signals it needs to grow. Without these vital growth signals, the cancer cell stops dividing and eventually dies.

FDA Approved Clinical Indications

Because brilanestrant is an investigational drug that was discontinued during clinical trials, it does not have any official FDA-approved uses for the general public.

Oncological Uses (Investigational)

• Historically studied for the treatment of postmenopausal women with advanced or metastatic Estrogen Receptor-positive (ER+), HER2-negative breast cancer.
• Studied for breast cancers that had become resistant to other hormone therapies (like tamoxifen or aromatase inhibitors).

Non-Oncological Uses

• There are no FDA-approved or investigational non-oncological uses for this drug.

Dosage and Administration Protocols

Because brilanestrant was strictly an investigational medicine, there is no single, commercially available prescription dosage. However, the dosing below reflects the protocols used during its Phase II clinical trials before development was halted.

• 
  Renal and Hepatic Insufficiency: Because the drug did not complete full Phase III trials, exact, standardized dose adjustments for severe kidney (renal) or liver (hepatic) disease were not fully established. Patients with severe liver or kidney problems were typically excluded from these early clinical trials.

Clinical Efficacy and Research Results

While brilanestrant is no longer in active development, oncological reviews and retrospective data analyses published between 2020 and 2025 frequently reference its trial results (such as trial NCT02569801) to understand how to build better SERDs.

• Effects on Disease Progression: In early clinical trials, brilanestrant successfully demonstrated the ability to lower the amount of estrogen receptors in tumors. General data showed it provided temporary disease stabilization for a subset of heavily pre-treated patients, preventing the cancer from growing for several months.
• Comparison to Standard of Care: The primary reason brilanestrant development was stopped was that it failed to show superior efficacy when directly compared to fulvestrant (an older, injectable SERD). While it was easier to take as a pill, the tumor shrinkage and overall survival rates did not beat the existing standard treatment.
• Paving the Way: The numerical data and safety profiles gathered from brilanestrant trials directly helped scientists develop the newer, successful oral SERDs (like elacestrant) that are currently gaining FDA approval and boasting longer progression-free survival rates today.

Safety Profile and Side Effects

Like all medications that block estrogen, brilanestrant caused side effects related to hormone deprivation. Because it is not FDA-approved, it does not carry a formal “Black Box Warning.”

Common Side Effects (>10%)

• Gastrointestinal Upset: Diarrhea, mild nausea, and stomach pain were the most commonly reported side effects.
• Fatigue: Feeling unusually tired or weak.
• Hot Flashes: Sudden feelings of warmth and sweating, similar to menopause symptoms.
• Joint and Muscle Pain (Arthralgia)

Serious Adverse Events

• Hepatotoxicity: Elevation in liver enzymes, indicating liver stress or inflammation.
• Thromboembolic Events (Rare): As with many anti-estrogen drugs, there is a slightly increased risk of blood clots forming in the legs or lungs.

Management Strategies

• Doctors managed diarrhea and nausea by advising patients to take over-the-counter anti-diarrheal medicines and anti-nausea drugs.
• If liver enzymes spiked to dangerous levels on blood tests, the research protocol required the doctor to lower the dose or pause the medication to let the liver heal.

Research Areas

While brilanestrant itself is not used in stem cell therapy, the class of drugs it belongs to (SERDs) is heavily researched in the context of overcoming Endocrine Resistance. Over time, breast cancer cells mutate and change their DNA (specifically the ESR1 gene) to survive despite hormone treatments. Brilanestrant was a pioneer in proving that “Targeted Degradation”—physically destroying the mutated protein rather than just blocking it—is a highly effective scientific strategy. Current regenerative and molecular research focuses on combining modern SERDs with other targeted therapies (like CDK4/6 inhibitors) to permanently cut off cancer cell survival pathways and prevent tumors from regenerating.

Patient Management and Practical Recommendations

(Note: Since brilanestrant is discontinued, these recommendations apply generally to patients participating in clinical trials for similar oral SERDs).

Pre-Treatment Tests to be Performed

• Tumor Biopsy/Genetic Testing: To confirm the breast cancer is ER-positive and check for specific ESR1 mutations.
• Baseline Blood Work: Comprehensive Metabolic Panel (CMP) to ensure healthy liver and kidney function before starting the drug.
• Electrocardiogram (ECG): To check baseline heart rhythm.

Precautions During Treatment

• Patients in these trials required frequent blood tests to monitor liver health.
• Extreme care was needed to watch for signs of blood clots, such as sudden leg swelling or shortness of breath.

Do’s and Don’ts

• DO tell your clinical trial team immediately if you experience severe diarrhea or vomiting, so you don’t become dehydrated.
• DO keep a diary of your symptoms (like hot flashes or joint pain) to share with your oncologist.
• DON’T take any herbal supplements (especially St. John’s Wort) or new vitamins without asking your doctor, as they can interfere with how your liver processes experimental cancer drugs.
• DON’T ignore sudden chest pain, shortness of breath, or a swollen, red calf—these could be signs of a serious blood clot and require emergency medical care.

Legal Disclaimer

The information provided in this guide is for educational and informational purposes only and does not constitute medical advice. Brilanestrant is an investigational product whose clinical development has been discontinued; it is not approved by the FDA for the treatment, cure, or prevention of any disease. Treatment protocols, dosages, and side effects vary by individual and by specific clinical trial guidelines. Patients should always consult with their primary oncologist or a qualified healthcare professional regarding diagnosis, treatment options, and the management of medical conditions. Do not disregard professional medical advice or delay in seeking it because of something you have read in this material.